 | Up a level |
Toyoda, Hidenori; Kanneganti, Mounika; Melendez-Torres, Jonathan; Parikh, Neehar D; Jalal, Prasun K; Piñero, Federico; Mendizabal, Manuel; Ridruejo, Ezequiel; Cheinquer, Hugo; Casadei-Gardini, Andrea; Weinmann, Arndt; Peck-Radosavljevic, Markus; Dufour, Jean-François; Radu, Pompilia; Shiha, Gamal; Soliman, Riham; Sarin, Shiv K; Kumar, Manoj; Wang, Jing-Houng; Tangkijvanich, Pisit; ... (2024). Regional differences in clinical presentation and prognosis of patients with post-sustained virologic response (SVR) hepatocellular carcinoma. Clinical gastroenterology and hepatology, 22(1), 72-80.e4. Elsevier 10.1016/j.cgh.2023.06.026
Lim, Ho Yeong; Merle, Philippe; Weiss, Karl Heinz; Yau, Thomas; Ross, Paul; Mazzaferro, Vincenzo; Blanc, Jean-Frédéric; Ma, Yuk Ting; Yen, Chia Jui; Kocsis, Judit; Choo, Su Pin; Sukeepaisarnjaroen, Wattana; Gérolami, René; Dufour, Jean-François; Gane, Edward J; Ryoo, Baek-Yeol; Peck-Radosavljevic, Markus; Dao, Thong; Yeo, Winnie; Lamlertthon, Wisut; ... (2018). Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma. Clinical cancer research, 24(19), pp. 4650-4661. American Association for Cancer Research 10.1158/1078-0432.CCR-17-3588
